Protein Discovery Could Lead To Development Of New Antiretroviral That Prevents HIV From Entering Cells, Study Says
Main Category: HIV / AIDSAlso Included In: Biology / Biochemistry
Article Date: 12 Oct 2007 - 6:00 PDT
| Patient / Public: | ![]() |
4.4 (5 votes) |
| Healthcare Prof: | ![]() |
4 (1 votes) |
The discovery of a type of peptide -- short proteins that include natural and artificial compounds such as hormones and antibiotics -- could lead to the development of a new antiretroviral drug that prevents HIV from entering human cells, according to a study published in the Oct. 9 issue of Proceedings of the National Academy of Sciences, the Salt Lake Tribune reports.
Michael Kay, an assistant professor of biochemistry at the University of Utah, and colleagues found that D peptides bind to a key component of HIV called a pocket, which helps the virus enter cells. The pocket is similar in all strains of the virus and is unable to mutate without affecting the virus' ability to enter cells, Kay said. The D peptide "basically" is a "knob that will fit into that pocket and block binding particles," preventing the virus from spreading among cells, Kay said.
Manufactured peptides have the potential to be taken orally and are "much more durable than natural peptides," Kay said, adding that natural peptides "generally make poor drugs because they must be injected and are readily degraded by the body." According to the Tribune, manufactured D peptides might be able to remain in the body for longer periods of time than natural peptides. A main component of the research -- which is being funded by NIH, the University of Utah Research Foundation and the American Cancer Society -- is the "attempt to anticipate and avoid drug resistance," according to Kay.
Preclinical trials and advanced laboratory studies of D peptides are under way to determine how well the peptides work. If the peptides are proved safe and effective, they could suppress the spread of the virus in HIV-positive people, preserve their immune systems and prevent transmission to HIV-negative people. A drug could be tested among humans within two years, according to the Tribune. In addition, a drug using D peptides could be used as a microbicide to prevent the spread of the virus in developing countries, the Tribune reports.
Although the research is in early stages, Kay said he hopes that the discovery will lead to the development of D peptide treatments for other viruses, such as Ebola and influenza (Rosetta, Salt Lake Tribune, 10/10).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our hiv / aids section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/85308.php>
APA
http://www.medicalnewstoday.com/releases/85308.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




